Drug – bio-affecting and body treating compositions – Radionuclide or intended radionuclide containing; adjuvant... – In an organic compound
Patent
1995-06-05
2000-02-15
Dees, Jose' G.
Drug, bio-affecting and body treating compositions
Radionuclide or intended radionuclide containing; adjuvant...
In an organic compound
544322, 544327, 544334, 546255, 546261, 568 61, 568 67, A61K 5104, C07D 3902, C07D21300, C07C31900
Patent
active
060249374
ABSTRACT:
The present invention provides aromatic amine substituted metal chelating compounds, chelates and chelate-targeting moiety conjugates formed from the chelating compounds, and methods for making and using these compounds. Metals capable of being chelated by the chelating compounds include radionuclides, such as .sup.99m Tc and .sup.186188 Re.
REFERENCES:
patent: 2977279 (1961-03-01), Kosmin
patent: 3027391 (1962-03-01), Frigerio
patent: 4293537 (1981-10-01), Wong
patent: 4421735 (1983-12-01), Haber et al.
patent: 4452774 (1984-06-01), Jones et al.
patent: 4673562 (1987-06-01), Davison et al.
patent: 4722892 (1988-02-01), Meares et al.
patent: 4732974 (1988-03-01), Nicolotti et al.
patent: 4746505 (1988-05-01), Jones et al.
patent: 4758682 (1988-07-01), Collins et al.
patent: 4789736 (1988-12-01), Canning et al.
patent: 4818813 (1989-04-01), Nowotnik et al.
patent: 4831122 (1989-05-01), Buchsbaum et al.
patent: 4861869 (1989-08-01), Nicolotti et al.
patent: 4863713 (1989-09-01), Goodwin et al.
patent: 4897255 (1990-01-01), Fritzberg et al.
patent: 4925650 (1990-05-01), Nosco et al.
patent: 4933456 (1990-06-01), Rocklage et al.
patent: 4959304 (1990-09-01), Simonson
patent: 4963682 (1990-10-01), Bodor
patent: 4963688 (1990-10-01), Bodor
patent: 4987227 (1991-01-01), Burrows et al.
patent: 5002754 (1991-03-01), Deutsch
patent: 5019497 (1991-05-01), Olsson
patent: 5026913 (1991-06-01), McBride et al.
patent: 5032678 (1991-07-01), Washino et al.
patent: 5037630 (1991-08-01), Fritzberg et al.
patent: 5057301 (1991-10-01), Wilbur et al.
patent: 5059541 (1991-10-01), Fritzberg et al.
patent: 5061641 (1991-10-01), Shochat et al.
patent: 5071965 (1991-12-01), Dunn et al.
patent: 5075099 (1991-12-01), Srinivasan et al.
patent: 5079346 (1992-01-01), Kung
patent: 5080884 (1992-01-01), McBride et al.
patent: 5089249 (1992-02-01), Fritzberg et al.
patent: 5091514 (1992-02-01), Fritzberg et al.
patent: 5104638 (1992-04-01), Nosco
patent: 5106951 (1992-04-01), Morgan, Jr. et al.
patent: 5112594 (1992-05-01), Woulfe et al.
patent: 5112595 (1992-05-01), Woulfe et al.
patent: 5112953 (1992-05-01), Gustavson et al.
patent: 5112954 (1992-05-01), Abrams et al.
patent: 5120526 (1992-06-01), Fritzberg et al.
patent: 5164176 (1992-11-01), Gustavson et al.
patent: 5167948 (1992-12-01), Wenzel
patent: 5169933 (1992-12-01), Anderson et al.
patent: 5175257 (1992-12-01), Kasina et al.
patent: 5175343 (1992-12-01), Fritzberg et al.
patent: 5220000 (1993-06-01), Theodorpulas
patent: 5225181 (1993-07-01), Srivastava et al.
patent: 5242679 (1993-09-01), Fritzberg et al.
patent: 5243073 (1993-09-01), Neumann et al.
patent: 5250666 (1993-10-01), Gustavson et al.
patent: 5252713 (1993-10-01), Morgan, Jr. et al.
patent: 5271927 (1993-12-01), Parker et al.
patent: 5279811 (1994-01-01), Bergstein et al.
patent: 5286848 (1994-02-01), Honzawa
patent: 5302370 (1994-04-01), Neumeier et al.
patent: 5310536 (1994-05-01), Srinivasan
patent: 5319143 (1994-06-01), Messersmith et al.
patent: 5322678 (1994-06-01), Morgan, Jr. et al.
patent: 5324502 (1994-06-01), Green et al.
patent: 5330737 (1994-07-01), Rajagopalan
patent: 5330738 (1994-07-01), Nosco
patent: 5371184 (1994-12-01), Rajagopalan et al.
patent: 5373093 (1994-12-01), Vallarino et al.
patent: 5382654 (1995-01-01), Lyle et al.
patent: 5476644 (1995-12-01), Illig et al.
patent: 5508458 (1996-04-01), Zhao
patent: 5608110 (1997-03-01), Ramalingam et al.
Bodor and Brewster, "Problems of Delivery of Drugs to the Brain," Pharmacology and Therapeutics 19(3): 337-386, 1983.
Bryson et al., "Protecting Groups in the Preparation of Thiolate Complexes of Technetium," Inorganic Chemistry 29(16): 2948-2951, 1990.
Cheesman et al., "Technetium-99m ECD: Ester-Derivatized Diamine-Dithiol Tc Complexes for Imaging Brain Perfusion," Journal of Nuclear Medicine 29(Suppl. 5): 788, abstract #197, 1988.
Ell, P., "Mapping Cerebral Blood Flow," Journal of Nuclear Medicine 33(10): 1843-1845, 1992.
Francesconi et al., "Technetium-99m N,N'-Bis(2-mercapto-2-methylpropyl)-2-aminobenzylamine: Technetium-99m Complexes of a Novel Bis(aminoethanethiol) Ligand," J. Med. Chem. 37: 3282-3288, 1994.
Goldstein and Betz, "The Blood-Brain Barrier," Scientific American 255(3): 74-83, 1986.
Holman and Devous, Sr., "Functional Brain SPECT: The Emergence of a Powerful Clinical Method," Journal of Nuclear Medicine 33(10): 1888-1904, 1992.
Holman et al., "Biodistribution, Dosimetry, and Clinical Evaluation of Technetium-99m Ethyl Cysteinate Dimer in Normal Subjects and in Patients with Chronic CerEbral Infarction," Journal of Nuclear Medicine 30(6): 1018-1024, 1989.
Ingold and Nathan, "Mechanism of, and Constitutional factors controlling, the Hydrolysis of Carboxylic Esters. Part VIII. Energies Associated with Induced Polar Effects in the Hydrolysis of Substituted Benzoic Esters," J. Chem. Soc.: 222-225, 1935.
Jaffe, H., "A Reexamination of the Hammett Equation," Chem. Rev.: 191-261, 1953.
Leveille et al., "Intrasubject Comparison Between Technetium-99m-ECD and Technetium-99m-HMPAO in Healthy Human Subjects," Journal of Nuclear Medicine 33(4): 480-484, 1992.
Leveille et al., "Characterization of Technetium-99m-L,L-ECD for Brain Perfusion Imaging, Part 2: Biodistribution and Brain Imaging in Humans," Journal of Nuclear Medicine 30(11): 1902-1910, 1989.
Mastrostamatis et al., "Tridentate Ligands Containing the SNS Donor Atom Set as a Novel Backbone for the Development of Technetium Brain-Imaging Agents," J. Med. Chem. 37: 3212-3218, 1994.
Matsuda et al., "Comparative SPECT Study of Stroke Using Tc-99m ECD, I-123 IMP, and Tc-99m HMPAO," Clinical Nuclear Medicine 18(9): 754-758, 1993.
Neves et al., "Neutral Technetium(II)-99m Complexes as potential Brain Perfusion Imaging Agents," Nucl. Med. Biol. 14(5): 503-510, 1987.
Orlandi et al., "Regional Cerebral Blood Flow and Distribution of [.sup.99m Tc]Ethyl Cysteinate Dimer in Nonhuman Primates," Stroke 21(7): 1059-1063, 1990.
Taylor et al., "Technetium-99-N1-(2-Mercapto-2-Methylpropyl)-N2-(2-Propargylthio-2-Methyl propyl)-1,2-Benzenediamine (t691): Preclinical Studies of a Potential New Tracer of Regional Cerebral Perfusion," Journal of Nuclear Medicine 33(10): 1836-1842, 1992.
Tedjamulia et al., "Evaluation of the Brain-specific Delivery of Radioiodinated (Iodophenyl)alkyl-Substituted Amines Coupled to a Dihydropyridine Carrier," J. Med. Chem. 28(11): 1574-1580, 1985.
Vallabhajosula et al., "TEchnetium-99m ECD: A New Brain Imaging Agent: In Vivo Kinetics and Biodistribution Studies in Normal Human Subjects," Journal of Nuclear Medicine 30(5): 599-604, 1989.
Walovitch et al., "Pharmocological Characterization of Tc99m ECD in Non-Human Primates as a New Agent for Brain Perfusion Imaging," Journal of Nuclear Medicine 29(Suppl. 5): 788, abstract #198, 1988.
Gursu et al., "The Reaction of N-Chloroacetylbenzamide With Some Aromatic Amines and Sysnthesis of Some Quaternary Pyridinium Compounds," J. Fac. Pharm. Istanbul 17:119-134, 1981.
Milligan et al., "Colorimetric Determination of Calcium Using Reagents of the Glyoxal Bis(2-hydroxyanil) Class," Analytical Chemistry 44(11):1822-1829, 1972.
Kasina Sudhakar
Reno John M.
Yau Eric
Dees Jos,e G.
Hartley Michael G.
NeoRx Corporation
LandOfFree
Aromatic amine substituted bridged nitrogen and sulfur donor ato does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Aromatic amine substituted bridged nitrogen and sulfur donor ato, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Aromatic amine substituted bridged nitrogen and sulfur donor ato will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1903446